3-12604191-G-T
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM2PM5PP2PP5_Very_Strong
The NM_002880.4(RAF1):c.779C>A(p.Thr260Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T260R) has been classified as Likely pathogenic.
Frequency
Consequence
NM_002880.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
RASopathy Pathogenic:2
This sequence change replaces threonine, which is neutral and polar, with lysine, which is basic and polar, at codon 260 of the RAF1 protein (p.Thr260Lys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Noonan syndrome (internal data). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 639302). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is expected to disrupt RAF1 function with a positive predictive value of 95%. This variant disrupts the p.Thr260 amino acid residue in RAF1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17603483; internal data). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Variant summary: RAF1 c.779C>A (p.Thr260Lys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251468 control chromosomes (gnomAD) )(ACMG PM2). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.779C>A in individuals affected with Noonan Syndrome And Related Conditions and no experimental evidence demonstrating its impact on protein function have been reported in the literature. Since its previous evaluation by our laboratory, a ClinVar submitter (evaluation after 2014) cites the variant as likely pathogenic, reporting it as de novo occurrence in an individual affected with Noonan syndrome (SCV000931334.1) (ACMG PM6). As parental testing was not conducted, this finding has not been independently corroborated at our laboratory. Other variants affecting the same codon or adjacent codons have been classified as pathogenic by our laboratory, in ClinVar database and reported in HGMD database as disease-associated (e.g. S259P, T260P, T260R, P261A, P261S, P261R, P261L), suggesting a possible mutational hotspot important for protein function (ACMG PM5). Nevertheless, at least one variant affecting the same codon (c.779C>T, p.Thr260Ile) is classified as VUS in ClinVar by the ClinGen RASopathy Variant Curation Expert Panel. Based on the evidence outlined above, the variant was re-classified as likely pathogenic. -
Noonan syndrome 5 Pathogenic:2
This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. -
PM2_Supporting+PP2+PS2+PS4_Supporting+PM5 -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at